Actively Recruiting
Evaluating the Safety and Effectiveness of Intravenous LAD328 Compared to Placebo in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Led by Almirall, S.A. · Updated on 2026-08-17
50
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effect of LAD328 compared to placebo in adults with moderate-to-severe Hidradenitis Suppurativa HS, a chronic skin condition affecting about 1% of the population. The study aims to assess the safety, tolerability, pharmacokinetics, and immune response to LAD328 in this group. This is a phase 2 randomized, double-blind, placebo-controlled trial. Participants will be randomly assigned to receive either LAD328 or a placebo, both given as intravenous infusions. The study includes a screening period of up to 4 weeks, followed by a 12-week double-blind treatment phase, and then an 8-week safety follow-up period. The total duration of participation is up to 20 weeks. During the trial, participants will be monitored regularly for treatment effects, safety, and side effects. Researchers will measure the proportion of participants achieving a 55% reduction in disease severity at week 12 using the International Hidradenitis Suppurativa Severity Score System IHS4-55. Additional assessments include reductions in clinical response scores, skin pain, and quality of life measures. Safety follow-up continues for 8 weeks after treatment ends.
CONDITIONS
Brief Title
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
Research Team
E
Estrella Garcia
A
Andrea Pejenaute
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here